Castle Biosciences Inc (CSTL) — Cash Flow-to-Debt Ratio
Castle Biosciences Inc (CSTL) has a Cash Flow-to-Debt Ratio of 0.24x as of September 2025, meaning its operating cash flow of $22.63 Million could theoretically repay 0% of its total liabilities ($95.74 Million) in one year. See free cash flow generation of Castle Biosciences Inc to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Castle Biosciences Inc Cash Flow-to-Debt Ratio (2017–2024)
Historical debt coverage capacity for Castle Biosciences Inc across 8 annual periods. Also explore Castle Biosciences Inc equity growth rate to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Castle Biosciences Inc (2017–2024)
Year-by-year debt coverage analysis for Castle Biosciences Inc. For market capitalisation and broader financial context, see CSTL market cap overview.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | 0.86x | $64.87 Million | $75.40 Million | ▲ +1049.1% |
| 2023 | -0.09x | $-5.63 Million | $62.07 Million | ▲ +89.5% |
| 2022 | -0.86x | $-41.66 Million | $48.18 Million | ▼ -131.5% |
| 2021 | -0.37x | $-18.98 Million | $50.83 Million | ▼ -189.5% |
| 2020 | 0.42x | $9.87 Million | $23.64 Million | ▲ +106.0% |
| 2019 | 0.20x | $7.01 Million | $34.63 Million | ▲ +153.5% |
| 2018 | -0.38x | $-12.29 Million | $32.47 Million | ▲ +25.4% |
| 2017 | -0.51x | $-12.23 Million | $24.09 Million | — |